Skip Navigation

Your Environment. Your Health.

Immunogenetic Differences between Caucasian Women with & without Silicone Implants in whom Myositis Develops

Clinical Center, Maryland

Supplementary Table. Comparisons of clinical signs and symptoms, myositis autoantibodies and local complications associated with the use of silicone implants between MASI patients and matched IIM or SIC study groups

 

  • Clinical Signs /
    Symptoms
    MASI,
    n=26
    n (%)
    IIM,
    n=52
    n (%)
    Fatigue26 (100)14 (26.9)
    Weight Loss11 (42.3)19 (36.5)
    Fatigue26 (100)47 (90.4)
    Raynaud's Sign11 (42.3)25 (48.1)
    Sjogren's Syndrome15 (57.7)19 (36.5)
    Proximal Weakness26 (100)46 (88.5)
    Distal Weakness12 (46.2)19 (36.5)
    Asymmetric Weakness5 (19.2)14 (26.9)
    Muscle Cramps9 (34.6)21 (40.4)
    Arthralgias19 (73.1)24 (46.2)
    Arthritis14 (53.8)19 (36.5)
    Falling5 (19.2)13 (25.0)
    Muscle Atrophy6 (23.1)19 (36.5)
    Contractures3 (11.5)4 (7.7)
    Carpel Tunnel4 (15.4)10 (19.2)
    Dyspnea (EX)16 (61.5)20 (38.5)
    Dyspnea (RE)7 (26.9)9 (17.3)
    O2 Use4 (15.4)6 (11.2)
    Changes Pulmonary Funct.7 (26.9)9 (17.3)
    Interstitial Lung Disease8 (30.8)11 (21.2)
    Cough5 (19.2)11 (21.2)
    Chest Pain2 (7.7)5 (9.6)
    Palpitation5 (19.2)15 (28.8)
    Edema13 (50.0)16 (30.8)
    Syncope0 (0)2 (3.8)
    Dysphagia12 (46.2)24 (46.2)
    Regurgitation5 (19.2)7 (13.5)
    Diarrhea2 (7.7)6 (11.2)
    Heliotrope Rash9 (34.6)19 (36.5)
    V Sign Rash5 (19.2)10 (19.2)
    Shawl Sign Rash3 (11.5)12 (23.1)
    Gottron's Papules10 (38.5)17 (32.7)
    Other Rashes4 (15.4)17 (32.7)
    Mechanic's Hands4 (15.4)7 (13.5)
    Nailbed Changes4 (15.4)6 (11.2)
    Cuticular Overgrowth3 (11.5)6 (11.2)
    Lymphadenopathy3 (11.5)1 (1.9)
  • Myositis-Specific
    Autoantibodies
    (MSA)
    MASI,
    n=26
    n (%)
    IIM,
    n=51**
    n (%)
    MSA8 (30.8)22 (43.1)
    Synthetase5 (19.2)18 (35.3)
    Jo-13 (11.5)14 (27.5)
    THR1 (3.8)3 (5.9)
    ILE1 (3.8)1 (2.0)
    Mi-22 (7.7)3 (5.9)
    SRP1 (3.8)1 (2.0)


    Myositis-Associated
    Autoantibodies
    (MAA)
    MASI,
    n=26
    n (%)
    IIM,
    n=51**
    n (%)
    MAA6 (23.1)16 (31.4)
    KU0 (0)0 (0)
    LA0 (0)5 (9.8)
    RO3 (11.5)6 (11.8)
    PM/Scl0 (0)1 (2.0)
    SM0 (0)2 (3.9)
    RNP3 (11.5)2 (3.9)


    Local
    Complications
    MASI,
    n=26
    n (%)
    SIC,
    n=52**
    n (%)
    Contracture12 (46.2)29 (55.8)
    Rupture8 (30.8)18 (34.6)
    Pain6 (23.1)11 (21.2)
    Infection3 (11.5)5 (9.6)
    Bleeding0 (0)7 (13.5)
    Lumps/Asymmetry7 (26.9)9 (17.3)
    LNE4 (15.4)8 (15.4)
    Explants17 (65.4)28 (53.8)

 

* Abbreviations per manuscript Table 1 and Jo-1, anti-histidyl tRNA synthetase; THR, anti-threonyl tRNA synthetase; ILE, anti-isoleucyl tRNA synthetase; Mi-2, anti-Mi-2; SRP, anti-signal recognition particle; LNE, lymph node enlargement. There were no significant differences (after correction for multiple comparisons) regarding these data among the groups.
**Serum was unavailable for 1 of 52 IIM patients.

Back to Top